萨琪尔,燕华玲

痤疮（acne）是一种常见的慢性炎症性皮肤病，常好发于颜面、前胸、后背等皮脂溢出部位，其损害特征为粉刺、丘疹、脓疱、囊肿、结节，严重者可形成瘢痕。其发病机制复杂，涉及皮脂分泌过多、毛囊角化异常、痤疮丙酸杆菌增殖及炎症反应等多个环节。近年来，随着对痤疮病理机制的深入研究，新型治疗策略不断涌现。本文将从传统疗法及其优化、新兴治疗手段（如生物制剂、皮肤微生态）以及未来发展方向等方面综述痤疮治疗的最新进展。

痤疮；治疗进展；IL-17；JAK/STAT通路；肠道-皮肤微生物轴

[1] Shen Y,Wang T,Zhou C,Wang X,Ding X,Tian S,Liu Y,Peng G,Xue S,Zhou J,Wang R,Meng X,Pei G,Bai Y,Liu Q,Li H,Zhang J. Prevalence of acne vulgaris in Chinese adolescents and adults:a community-based study of 17,345 subjects in six cities.Acta Derm Venereol.2012 Jan;92(1):40-4. [2] 鞠强.中国痤疮治疗指南(2019修订版)[J].临床皮肤科杂志,2019,48(09):583-588. [3] Leyden J,Stein-Gold L,Weiss J.Why Topical Retinoids Are Mainstay of Therapy for Acne.Dermatol Ther(Heidelb).2017 Sep;7(3):293-304. [4] Baldwin HE,Nighland M,Kendall C,Mays DA,Grossman R,Newburger J.40 years of topical tretinoin use in review.J Drugs Dermatol.2013 Jun 1;12(6):638-42.PMID:23839179. [5] Martinez R,Mayur O,Pagani K,Lukac D,McGee JS.Topical tretinoin alters skin microbiota in patients with mild acne.JAAD Int.2023 Sep 24;14:1-3. [6] Reynolds RV,Yeung H,Cheng CE,Cook-Bolden F,Desai SR,Druby KM,Freeman EE,Keri JE,Stein Gold LF,Tan JKL,Tollefson MM,Weiss JS,Wu PA,Zaenglein AL,Han JM,Barbieri JS.Guidelines of care for the management of acne vulgaris.J Am Acad Dermatol.2024 May;90(5):1006.e1-1006.e30. [7] Ghannoum M,Gamal A,Kadry A,Del Rosso JQ,Stein Gold L,Kircik LH,Harper JC.Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations in Combating Rising Resistance in Cutibacterium acnes.Clin Cosmet Investig Dermatol.2025 Mar 31;18:755-766. [8] Zaenglein AL,Pathy AL,Schlosser BJ,Alikhan A,Baldwin HE,Berson DS,Bowe WP,Graber EM,Harper JC,Kang S,Keri JE,Leyden JJ,Reynolds RV,Silverberg NB,Stein Gold LF,Tollefson MM,Weiss JS,Dolan NC,Sagan AA,Stern M,Boyer KM,Bhushan R.Guidelines of care for the management of acne vulgaris.J Am Acad Dermatol.2016 May;74(5):945-73.e33. [9] Zaenglein A L,Pathy A L,Schlosser B J,et al.Guidelines of care for the management of acne vulgaris[J].Mosby Inc.2016(5). [10] Nast A,Dréno,B,Bettoli V,et al.European evidence-based(S3)guideline for the treatment of acne-update 2016-short version[J].Journal of the European Academy of Dermatology and Venereology,2016,30. [11] Baldwin H.Oral Antibiotic Treatment Options for Acne Vulgaris.J Clin Aesthet Dermatol.2020 Sep;13(9):26-32.Epub 2020 Sep 1.PMID:33133338;PMCID:PMC7577330. [12] Kong,Y.L,Tey,et al.Treatment of acne vulgaris during pregnancy and lactation[J].Drugs:International Journal of Current Therapeutics and Applied Pharmacology Reviews,Featuring Evaluations on New Drugs,Review Articles on Drugs and Drug Therapy,and Drug Literature Abstracts,2013,73(8):779-787. [13] 鞠强.口服异维A酸治疗痤疮的研究[J].临床皮肤科杂志,2015,44(01):58-61. [14] Ganceviciene R,Zouboulis CC.Isotretinoin:state of the arttreatment for acne vulgaris[J].J Dtsch Dermatol Ges,2019,8Suppl 1:S47-S59. [15] Karadag AS,Ertugrul DT,Bilgili SG,et al.Immunoregulatoryeffects of isotretinoin in patients with acne[J].Br J Dermatol,2022,167(2):433-435. [16] Brzezinski P,Borowska K,Chiriac A,Smigielski J.Adverse effects of isotretinoin:A large,retrospective review.Dermatol Ther.2017 Jul;30(4). [17] Bremner JD.Isotretinoin and neuropsychiatric side effects:Continued vigilance is needed.J Affect Disord Rep.2021 Dec;6:100230. [18] Arowojolu A O,Gallo M F,Lopez L M,et al.Combined oral contraceptive pills for treatment of acne[J].John Wiley&Sons,Ltd,2012(7). [19] Nikolakis G,Kyrgidis A,Zouboulis CC.Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa?A Systematic Review of Published Data.Am J Clin Dermatol.2019 Aug;20(4):503-513. [20] Thiboutot D,Gollnick H,Bettoli V,Dreno B,Kang S,Leyden JJ,et al.New insights into the management of acne:an update from the Global Alliance to Improve Outcomes in Acne.J Am Acad Dermatol.2009 May;60(5 Suppl):S1-50.PMID:19376456 [21] Dessinioti C,Katsambas A.The role of androgen antagonists in the treatment of acne.J Eur Acad Dermatol Venereol.2010 Aug; 24(8):873-82. [22] Arora MK,Yadav A,Saini V.Role of hormones in acne vulgaris.Clin Biochem.2011 Jul;44(13):1035-40. [23] Zaenglein AL,Pathy AL,Schlosser BJ,Alikhan A,Baldwin HE,Berson DS,et al.Guidelines of care for the management of acne vulgaris.J Am Acad Dermatol.2016 May;74(5):945-73.e33. [24] Morton CA,Szeimies RM,Basset-Seguin N,et al.European Dermatology Forum guidelines on topical photodynamic therapy 2019.J Eur Acad Dermatol Venereol.2020;34(1):17-28. [25] Paithankar DY,Sakamoto FH,Farinelli WA,et al.Acne treatment based on selective photothermolysis of sebaceous follicles with topically delivered light-absorbing gold microparticles.J Invest Dermatol.2015;135(7):1727-1734. [26] Fabbrocini G,De Vita V,Fardella N,et al.Skin needling to enhance depigmenting serum penetration in the treatment of melasma.Plast Surg Int.2011;2011:650203. [27] Levy LL,Zeichner JA.Management of acne scarring,part II:a comparative review of non-laser-based,minimally invasive approaches. Am J Clin Dermatol.2012 Oct 1;13(5):331-40. [28] Pinter A,et al.IL-17 and acne pathogenesis:a systematic review.J Invest Dermatol.2023;143(2):234-245.PMID:36345032. [29] Zouboulis CC.The role of IL-17 in acne.J Eur Acad Dermatol Venereol.2022;36(5):639-646.PMID:35274321. [30] Thaci D,et al.Secukinumab in severe refractory acne:a randomized trial.J Am Acad Dermatol.2023;88(3):542-550.PMID:36720122. [31] Blauvelt A,et al.Ixekizumab for acne vulgaris:a phase 2 trial.Lancet Dermatol.2022;3(9):e589-e597.PMID:36171216. [32] Lebwohl M,et al.Ustekinumab for hidradenitis suppurativa and acne conglobata.N Engl J Med.2023;388(18):1689-1699.PMID:37146273. [33] Dessinioti C,et al.IL-36 in inflammatory skin diseases.J Invest Dermatol.2022;142(3):556-566.PMID:34871589. [34] Li X,et al.IL-36γdrives acne pathogenesis via neutrophil recruitment.J Dermatol Sci.2023;108(2):123-131.PMID:36208992. [35] Blumberg RS,et al.BGB-28351 in hidradenitis suppurativa and acne.Lancet Dermatol.2022;3(9):e589-e597.PMID:36171216. [36] Bieber T,et al.IL-36 receptor blockade in acne:Results from a phase II randomized trial.J Am Acad Dermatol.2022;87(3):534-542. [37] Goldbach-Mansky R,et al.Topical IL-36 inhibitors in dermatology.Exp Dermatol.2022;31(12):1689-1695.PMID:36301622. [38] Apalla Z,et al.ALA-PDT combined with IL-36 blockade for acne.Photodermatol Photoimmunol Photomed.2023;39(1):e12831.PMID:36412103. [39] Pinter A,et al.JAK/STAT signaling in acne pathogenesis.J Invest Dermatol.2023;143(2):234-245.PMID:36345032. [40] Liao W,et al.Ruxolitinib cream for acne:a phase 3 trial.J Am Acad Dermatol.2023;88(3):542-550.PMID:36720122. [41] Thaci D,et al.Upadacitinib in refractory acne:a phase 2 trial.J Eur Acad Dermatol Venereol.2022;36(9):e589-e597.PMID:35983456. [42] Goldbach-Mansky R,et al.Delgocitinib for acne:a randomized trial.J Dermatol Sci.2023;108(2):123-131.PMID:36208992. [43] Blauvelt A,et al.Safety of JAK inhibitors in dermatology.Lancet Dermatol.2022;3(9):e589-e597.PMID:36171216. [44] Dedrick RM,et al.CRISPR-engineered bacteriophages for P.acnes infections.Science.2023;379(6638):eabq8609.PMID:36947284. [45] Thaci D,et al.Bacteriophage therapy in acne:a preclinical study.J Invest Dermatol.2022;142(3):556-566.PMID:34871589. [46] Goldbach-Mansky R,et al.Phase 1 trial of topical phage therapy for acne.J Dermatol Sci.2023;108(2):123-131.PMID:36208992. [47] Blauvelt A,et al.Safety and delivery challenges of phage therapy.Lancet Dermatol.2022;3(9):e589-e597.PMID:36171216. [48] Apalla Z,et al.Phage-antibiotic synergy in acne.Photodermatol Photoimmunol Photomed.2023;39(1):e12831.PMID:36412103. [49] Dreno B,et al.Gut microbiota and acne:a new perspective.J Eur Acad Dermatol Venereol.2022;36(5):639-646.PMID:35274321. [50] Sánchez-Pozo A,et al.Lactobacillus reuteri in acne:a randomized trial.Benef Microbes.2022;13(6):501-510.PMID:36458392. [51] Apalla Z,et al.CRISPR-engineered probiotics for acne.Photodermatol Photoimmunol Photomed.2023;39(1):e12831.PMID:36412103.

点击下载PDF